Pandion is focused on developing therapeutics for a wide range of autoimmune and inflammatory indications.

We are rapidly advancing our lead program, an IL-2 mutein fusion protein that preferentially expands T regulatory cells, to the clinic while supporting a robust pipeline of systemic immune modulators and targeted therapeutics focused on the gut, liver, skin, kidneys, and pancreas.

Primary indications for current programs include:

  • Inflammatory bowel disease
  • Autoimmune liver diseases
  • Autoimmune skin conditions
  • Various kidney indications
  • Type 1 diabetes